OA09.06 IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC

著者: Caicun Zhou, Xue Dong, Gang Chen, Zhenning Wang, Xiaolong Wu, Yuan Yao, Yakun Zhang, Ying Cheng, Hongming Pan, Xiaolei Zhang, Jiuwei Cui, L. Wang, X. Chen, Xiaohua Li, Zhenning Wang, Qun Wang, Jianxing He, May D. Wang, Isabell Yan, Lei Qian, Ah Reum An, Ailu Cai, Qian Wu, M. Ballinger, L. Wang - Journal of Thoracic Oncology 2023 被引用: 47

In IMpower150 (NCT02366143), 1L atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) plus carboplatin and paclitaxel significantly improved PFS and OS vs bevacizumab plus carboplatin and paclitaxel in metastatic nonsquamous NSCLC (nsqNSCLC) without EGFR/ALK alterations (Socinski et al. NEJM 2018). This led to global approval of atezolizumab plus bevacizumab and chemotherapy as 1L treatment for metastatic nsqNSCLC. To address regional differences in patient genomic composition (e.g., EGFR mutation prevalence rates) and clinical practice (e.g., pemetrexed use), the Phase III IMpower151 (NCT04194203) study was conducted in China to evaluate the efficacy and safety of atezolizumab, bevacizumab, carboplatin, plus paclitaxel or pemetrexed (ABCP) vs BCP, as 1L treatment for metastatic nsqNSCLC.